Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures

Neuropharmacology

Volumn 51, Issue 2, 2006, Pages 283-294

  Boscia, Francesca ^a   Annunziato, Lucio ^a   Taglialatela, Maurizio ^a,b  

^a Special Section of Surgical Digestive Endoscopy   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Dentate gyrus; Excitotoxicity; Flupirtine; Neuroprotection; Organotypic hippocampal cultures; Oxidative stress; Retigabine

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; DIZOCILPINE; FLUPIRTINE; GLUCOSE; LINOPIRDINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; OXYGEN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ1; REACTIVE OXYGEN METABOLITE; RETIGABINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN INJURY; BRAIN REGION; BRAIN SLICE; CELL DEATH; CONTROLLED STUDY; DENTATE GYRUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; HIPPOCAMPUS; IC 50; MOLECULAR DYNAMICS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REOXYGENATION; TISSUE CULTURE;

AMINOPYRIDINES; ANIMALS; CARBAMATES; CULTURE MEDIA, SERUM-FREE; GLUCOSE; HIPPOCAMPUS; KCNQ POTASSIUM CHANNELS; N-METHYLASPARTATE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXYGEN; PHENYLENEDIAMINES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, N-METHYL-D-ASPARTATE; TISSUE CULTURE TECHNIQUES;

EID: 33745965631     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.03.024     Document Type: Article

References (63)

1. Abdel-Hamid K.M., and Tymianski M. Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J. Neurosci. 17 (1997) 3538-3553
2. Barnham K.J., Masters C.L., and Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3 (2004) 205-214
3. Biervert C., Schroeder B.C., Kubisch C., Berkovic S.F., Propping P., Jentsch T.J., and Steinlein O.K. A potassium channel mutation in neonatal human epilepsy. Science 279 (1998) 403-406
4. Blackburn-Munro G., and Jensen B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. 460 (2003) 109-116
5. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., and Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11 (2005) 1-20
6. Block F., Pergande G., and Schwarz M. Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats. Brain Res. 754 (1997) 279-284
7. Calabresi P., Cupini L.M., Centonze D., Pisani F., and Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann. Neurol. 53 (2003) 693-702
8. Castaldo P., Miraglia del Giudice E., Coppola G., Pascotto A., Annunziato L., and Taglialatela M. Benign familial neonatal convulsions caused by altered gating of KCNQ2/KCNQ3 potassium channels. J. Neurosci. 22 (2002) RC199
9. Cooper E.C., Harrington E., Jan Y.N., and Jan L.Y. M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J. Neurosci. 21 (2001) 9529-9540
10. D'Mello S.R., and Chin P.C. Treating neurodegenerative conditions through the understanding of neuronal apoptosis. Curr. Drug Targets CNS Neurol. Disord. 1 (2005) 3-23
11. Dorr J., Roth K., Zurbuchen U., Deisz R., Bechmann I., Lehmann T.N., Meier S., Nitsch R., and Zipp F. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J. Neuroimmunol. 167 (2005) 204-209
12. Dost R., Rostock A., and Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 382-390
13. Dupuis D.S., Schroder R.L., Jespersen T., Christensen J.K., Christophersen P., Jensen B.S., and Olesen S.P. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. J. Pharmacol. 437 (2002) 129-137
14. Ebert U., Brandt C., and Loscher W. Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia 43 Suppl. (2002) 86-95
15. Ferron G.M., Paul J., Fruncillo R., Richards L., Knebel N., Getsy J., and Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J. Clin. Pharmacol. 42 (2002) 175-182
16. Foster A.C., Gill R., and Woodruff G.N. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8 (1988) 4745-4754
17. Freund T.F., and Buzsaki G. Interneurons of the hippocampus. Hippocampus 6 (1996) 347-470
18. Friedel H.A., and Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 45 (1993) 548-569
19. Gassen M., Pergande G., and Youdim M.B. Antioxidant properties of the triaminopyridine, flupirtine. Biochem. Pharmacol. 56 (1998) 1323-1329
20. Gribkoff V.K., Starrett Jr. J.E., Dworetzky S.I., Hewawasam P., Boissard C.G., Cook D.A., Frantz S.W., Heman K., Hibbard J.R., Huston K., Johnson G., Krishnan B.S., Kinney G.G., Lombardo L.A., Meanwell N.A., Molinoff P.B., Myers R.A., Moon S.L., Ortiz A., Pajor L., Pieschl R.L., Post-Munson D.J., Signor L.J., Srinivas N., Taber M.T., Thalody G., Trojnacki J.T., Wiener H., Yeleswaram K., and Yeola S.W. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 7 (2001) 471-477
21. Harry G.J., and Lefebvre d'Hellencourt C. Dentate gyrus: alterations that occur with hippocampal injury. Neurotoxicology 24 (2003) 343-356
22. Ikegaya Y., and Matsuki N. Regionally selective neurotoxicity of NMDA and colchicine is independent of hippocampal neural circuitry. Neuroscience 113 (2002) 253-256
23. Jarrard L.E. Use of excitotoxins to lesion the hippocampus: update. Hippocampus 12 (2002) 405-414
24. Kapetanovic I.M., Yonekawa W.D., and Kupferberg H.J. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res. 22 (1995) 167-173
25. Koh J.Y., Gwag B.J., Lobner D., and Choi D.W. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 268 (1995) 573-575
26. Kornhuber J., Bleich S., Wiltfang J., Maler M., and Parsons C.G. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2 + block via activation of voltage independent potassium channels. J. Neural Transm. 106 (1999) 857-867
27. Korsgaard M.P., Hartz B.P., Brown W.D., Ahring P.K., Strobaek D., and Mirza N.R. Anxiolytic effects of maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 314 (2005) 282-292
28. Kovacs R., Schuchmann S., Gabriel S., Kann O., Kardos J., and Heinemann U. Free radical-mediated cell damage after experimental status epilepticus in hippocampal slice cultures. J. Neurophysiol. 88 (2002) 2909-2918
29. Kristensen B.W., Noraberg J., and Zimmer J. Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. Brain Res. 917 (2001) 21-44
30. Kristensen B.W., Noer H., Gramsbergen J.B., Zimmer J., and Noraberg J. Colchicine induces apoptosis in organotypic hippocampal slice cultures. Brain Res. 964 (2003) 264-278
31. Leker R.R., and Neufeld M.Y. Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain Res. Rev. 4 (2003) 187-203
32. Levy S.L., Burnham W.M., and Hwang P.A. An evaluation of the anticonvulsant effects of vitamin E. Epilepsy Res. 6 (1990) 12-17
33. Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 79 (1999) 1431-1568
34. Liu R., Liu W., Doctrow S.R., and Baudry M. Iron toxicity in organotypic cultures of hippocampal slices: role of reactive oxygen species. J. Neurochem. 85 (2003) 492-502
35. Lowenstein D.H., Thomas M.J., Smith D.H., and McIntosh T.K. Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus. J. Neurosci. 12 (1992) 4846-4853
36. Main M.J., Cryan J.E., Dupere J.R.B., Cox B., Clare J.J., and Burbidge S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 58 (2000) 253-262
37. Martire M., Castaldo P., D'Amico M., Preziosi P., Annunziato L., and Taglialatela M. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J. Neurosci. 24 (2004) 592-597
38. Muller W.E., Romero F.J., Perovic S., Pergande G., and Pialoglou P. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J. Neurochem. 68 (1997) 2371-2377
39. Ordy J.M., Wengenack T.M., Bialobok P., Coleman P.D., Rodier P., Baggs R.B., Dunlap W.P., and Kates B. Selective vulnerability and early progression of hippocampal CA1 pyramidal cell degeneration and GFAP-positive astrocyte reactivity in the rat four-vessel occlusion model of transient global ischemia. Exp. Neurol. 119 (1993) 128-139
40. Osborne N.N., Schwarz M., and Pergande G. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophthalmol. Vis. Sci. 37 (1996) 274-280
41. Otto M., Cepek L., Ratzka P., Doehlinger S., Boekhoff I., Wiltfang J., Irle E., Pergande G., Ellers-Lenz B., Windl O., Kretzschmar H.A., Poser S., and Prange H. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 62 (2004) 714-718
42. Pellegrini-Giampietro D.E., Peruginelli F., Meli E., Cozzi A., Albani-Torregrossa S., Pellicciari R., and Moroni F. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology 38 (1999) 1607-1619
43. Perovic S., Schleger C., Pergande G., Iskric S., Ushijima H., Rytik P., and Muller W.E. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-d-aspartate and gp120 of HIV-1. Eur. J. Pharmacol. 288 (1994) 27-33
44. Perovic S., Pergande G., Ushijima H., Kelve M., Forrest J., and Muller W.E. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 4 (1995) 369-374
45. Perovic S., Schroder H.C., Pergande G., Ushijima H., and Muller W.E. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp. Neurol. 147 (1997) 518-524
46. Peters O., Back T., Lindauer U., Busch C., Megow D., Dreier J., and Dirnagl U. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab. 18 (1998) 196-205
47. Raju G.B., Behari M., Prasad K., and Ahuja G.K. Randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopherol (vitamin E) as add-on therapy in uncontrolled epilepsy. Epilepsia 35 (1994) 368-372
48. Ratzliff A.H., Santhakumar V., Howard A., and Soltesz I. Mossy cells in epilepsy: rigor mortis or vigor mortis?. Trends Neurosci. 25 (2002) 140-144
49. Rekling J.C. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci. Lett. 335 (2003) 167-170
50. Rivera S., Guillot S., Agassandian C., Ben Ari Y., and Khrestchatisky M. Serum deprivation-induced apoptosis in cultured hippocampi is prevented by kainate. Neuroreport 9 (1998) 3949-3953
51. Rostock A., Tober C., Rundfeldt C., Bartsch R., Engel J., Polymeropoulos E.E., Kutscher B., Loscher W., Honack D., White H.S., and Wolf H.H. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23 (1996) 211-223
52. Rundfeldt C., and Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett. 282 (2000) 73-76
53. 2+ concentration. Eur. J. Pharmacol. 294 (1995) 469-473
54. Satoh T., Sakai N., Enokido Y., Uchiyama Y., and Hatanaka H. Survival factor-insensitive generation of reactive oxygen species induced by serum deprivation in neuronal cells. Brain Res. 733 (1996) 9-14
55. Seyfried J., Evert B.O., Rundfeldt C., Schulz J.B., Kovar K.A., Klockgether T., and Wullner U. Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur. J. Pharmacol. 400 (2000) 155-166
56. Singh N.A., Charlier C., Stauffer D., DuPont B.R., Leach R.J., Melis R., Ronen G.M., Bjerre I., Quattlebaum T., Murphy J.V., McHarg M.L., Gagnon D., Rosales T.O., Peiffer A., Anderson V.E., and Leppert M. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. 18 (1998) 25-29
57. Szelenyi I., Nickel B., Borbe H.O., and Brune K. Mode of antinociceptive action of flupirtine in the rat. Br. J. Pharmacol. 97 (1989) 835-842
58. Vornov J.J., Tasker R.C., and Coyle J.T. Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures. Exp. Neurol. 114 (1991) 11-22
59. Wang H.S., Pan Z., Shi W., Brown B.S., Wymore R.S., Cohen I.S., Dixon J.E., and McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282 (1998) 1890-1893
60. Wang H.S., Brown B.S., McKinnon D., and Cohen I.S. Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol. Pharmacol. 57 (2000) 1218-1223
61. Wickenden A.D., Yu W., Zou A., Jegla T., and Wagoner P.K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 58 (2000) 591-600
62. Wood J.P., Pergande G., and Osborne N.N. Prevention of Glutathione Depletion-Induced Apoptosis in Cultured Human RPE Cells by Flupirtine. Restor. Neurol. Neurosci. 12 (1998) 119-125
63. Zaczek R., Chorvat R.J., Saye J.A., Pierdomenico M.E., Maciag C.M., Logue A.R., Fisher B.N., Rominger D.H., and Earl R.A. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. 285 (1998) 724-730